Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
TriSalus Life Sciences, Inc. - Common Stock
(NQ:
TLSI
)
4.550
+0.180 (+4.12%)
Streaming Delayed Price
Updated: 1:57 PM EDT, Jun 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about TriSalus Life Sciences, Inc. - Common Stock
< Previous
1
2
3
Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
June 23, 2026
From
Pomerantz LLP
Via
GlobeNewswire
TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm
June 17, 2026
From
Schall Law
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
June 16, 2026
From
Pomerantz LLP
Via
GlobeNewswire
TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm
June 10, 2026
From
Schall Law
Via
GlobeNewswire
TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
June 10, 2026
From
TriSalus Life Sciences
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
June 09, 2026
From
Pomerantz LLP
Via
GlobeNewswire
TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm
June 03, 2026
From
The Schall Law Firm
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI
June 02, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
May 20, 2026
From
Glancy Prongay Wolke & Rotter LLP
Via
Business Wire
TriSalus Life Sciences Inc. (TLSI) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
May 20, 2026
From
Law Offices of Howard G. Smith
Via
Business Wire
TLSI Investor Alert: Levi & Korsinsky Investigates TLSI (TLSI) for Potential Securities Fraud
May 19, 2026
From
Levi & Korsinsky, LLP
Via
Business Wire
Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
May 19, 2026
From
The Law Offices of Frank R. Cruz
Via
Business Wire
TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth
May 12, 2026
From
TriSalus Life Sciences
Via
Business Wire
Real-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge Avoidance
May 12, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors
May 04, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference Call
April 28, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting
April 09, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer
April 07, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models
March 18, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance
March 05, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference Call
February 25, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering
February 20, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Proposes Public Offering
February 19, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors
February 09, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance
January 12, 2026
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025
December 04, 2025
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™
November 18, 2025
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance
November 13, 2025
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences to Participate in Upcoming Investor Conferences
November 11, 2025
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025
November 10, 2025
From
TriSalus Life Sciences
Via
Business Wire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
